Recently a small cancer study showed the unprecedented result of 100 percent of participants in remission. A study at Memorial Sloan Kettering Cancer Center in New York showed encouraging results using immunotherapy treatment with the drug Dostralimab.
The trial’s participants all had tumors with the abnormality known as mismatch repair (MMR) deficiency, a mutation that occurs in between 5 and 10 percent of rectal cancer cases and is also present in endometrial, bladder, breast and prostate tumors. Specific mutated tumors tend to be more resistant to traditional therapies. These results show that is it possible to tailor immunotherapy drugs towards these mutations
18 early-stage colorectal cancer patients in the Sloan Kettering trial, which began in late 2019, with the same tumor mutation (MMR) who had no prior treatment, received dostarlimab every three weeks over six months. Tumors completely disappeared in 14 patients who had completed the treatment by the time the study and none have required follow-up treatment.
This is the first-time immunotherapy alone has shown that the need for chemotherapy, radiation or surgery, could be eliminated.
(Link provided by NPR.org. NPR neither promotes nor endorses any third party’s causes, ideas, sites, products or services.)
Photo Courtesy Freepik/pressfoto Free Lic CC00